wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38372369-2E161D39-110D-47B5-8382-38EEE7DE2776
Q38372369-2E161D39-110D-47B5-8382-38EEE7DE2776
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38372369-2E161D39-110D-47B5-8382-38EEE7DE2776
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
P2860
Q38372369-2E161D39-110D-47B5-8382-38EEE7DE2776
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38372369-2E161D39-110D-47B5-8382-38EEE7DE2776
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
faa36ad4a8ef62fc3d318765348921a14e3fdf20
P2860
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.